Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan
· Delayed Price · Currency is JPY 4,278.00
+73.00 (1.74%)
Feb 5, 2025, 3:30 PM JST
Kaken Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 87,245 | 72,044 | 72,984 | 76,034 | 74,979 | 89,232 | Upgrade
|
| Revenue Growth (YoY) | 20.61% | -1.29% | -4.01% | 1.41% | -15.97% | -5.24% | Upgrade
|
| Cost of Revenue | 34,324 | 33,505 | 33,428 | 34,458 | 34,073 | 38,751 | Upgrade
|
| Gross Profit | 52,921 | 38,539 | 39,556 | 41,576 | 40,906 | 50,481 | Upgrade
|
| Selling, General & Admin | 16,246 | 16,165 | 15,476 | 15,833 | 16,155 | 17,320 | Upgrade
|
| Research & Development | 12,778 | 12,543 | 15,789 | 8,420 | 6,736 | 6,418 | Upgrade
|
| Operating Expenses | 29,341 | 29,025 | 31,556 | 24,511 | 23,118 | 23,969 | Upgrade
|
| Operating Income | 23,580 | 9,514 | 8,000 | 17,065 | 17,788 | 26,512 | Upgrade
|
| Interest Expense | -21 | -17 | -17 | -17 | -17 | -17 | Upgrade
|
| Interest & Investment Income | 527 | 479 | 438 | 396 | 393 | 392 | Upgrade
|
| Currency Exchange Gain (Loss) | -59 | -59 | - | -31 | -12 | -50 | Upgrade
|
| Other Non Operating Income (Expenses) | 23 | 32 | 306 | 129 | 69 | 110 | Upgrade
|
| EBT Excluding Unusual Items | 24,050 | 9,949 | 8,727 | 17,542 | 18,221 | 26,947 | Upgrade
|
| Gain (Loss) on Sale of Investments | -537 | 13 | 1 | 1 | 115 | 3 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 1 | 195 | 379 | -2 | Upgrade
|
| Asset Writedown | -139 | -167 | -1,911 | -3,091 | -54 | -355 | Upgrade
|
| Other Unusual Items | -2 | - | -1 | -762 | -4 | -1 | Upgrade
|
| Pretax Income | 23,372 | 9,795 | 6,817 | 13,885 | 18,657 | 26,592 | Upgrade
|
| Income Tax Expense | 5,129 | 1,770 | 1,377 | 4,336 | 5,252 | 7,222 | Upgrade
|
| Net Income | 18,243 | 8,025 | 5,440 | 9,549 | 13,405 | 19,370 | Upgrade
|
| Net Income to Common | 18,243 | 8,025 | 5,440 | 9,549 | 13,405 | 19,370 | Upgrade
|
| Net Income Growth | 414.76% | 47.52% | -43.03% | -28.77% | -30.80% | 8.97% | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 39 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 39 | 39 | Upgrade
|
| Shares Change (YoY) | 0.88% | 0.44% | -1.07% | -1.59% | -1.41% | -1.84% | Upgrade
|
| EPS (Basic) | 481.73 | 212.66 | 144.79 | 251.44 | 347.37 | 494.89 | Upgrade
|
| EPS (Diluted) | 481.73 | 212.66 | 144.79 | 251.44 | 347.37 | 494.89 | Upgrade
|
| EPS Growth | 410.26% | 46.87% | -42.41% | -27.62% | -29.81% | 11.02% | Upgrade
|
| Free Cash Flow | 23,666 | 716 | 7,266 | 10,350 | 12,407 | 25,309 | Upgrade
|
| Free Cash Flow Per Share | 624.93 | 18.97 | 193.39 | 272.53 | 321.51 | 646.63 | Upgrade
|
| Dividend Per Share | 150.000 | 150.000 | 150.000 | 150.000 | 150.000 | 150.000 | Upgrade
|
| Gross Margin | 60.66% | 53.49% | 54.20% | 54.68% | 54.56% | 56.57% | Upgrade
|
| Operating Margin | 27.03% | 13.21% | 10.96% | 22.44% | 23.72% | 29.71% | Upgrade
|
| Profit Margin | 20.91% | 11.14% | 7.45% | 12.56% | 17.88% | 21.71% | Upgrade
|
| Free Cash Flow Margin | 27.13% | 0.99% | 9.96% | 13.61% | 16.55% | 28.36% | Upgrade
|
| EBITDA | 26,229 | 12,267 | 10,568 | 19,551 | 20,106 | 29,273 | Upgrade
|
| EBITDA Margin | 30.06% | 17.03% | 14.48% | 25.71% | 26.82% | 32.81% | Upgrade
|
| D&A For EBITDA | 2,649 | 2,753 | 2,568 | 2,486 | 2,318 | 2,761 | Upgrade
|
| EBIT | 23,580 | 9,514 | 8,000 | 17,065 | 17,788 | 26,512 | Upgrade
|
| EBIT Margin | 27.03% | 13.21% | 10.96% | 22.44% | 23.72% | 29.71% | Upgrade
|
| Effective Tax Rate | 21.95% | 18.07% | 20.20% | 31.23% | 28.15% | 27.16% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.